Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its development candidate LPCN ...

Objectives While diffuse alveolar haemorrhage (DAH) is recognised as a life-threatening complication of systemic lupus erythematosus (SLE), little ... 35–38 Again, given the likely complex ...

A 35-year-old man presents with a chief complaint of purple discoloration of his toes and associated skin lesions that have ...

This study is being conducted to evaluate the safety, tolerability, and ability to manufacture Descartes-08, an investigational mRNA CAR-T cell therapy, in people living with moderate to severe ...

And I'm here today to tell you some very exciting news. The American College of Rheumatology has just released the 2025 new guidelines on the treatment of systemic lupus. We could not be happier to ...

MANCHESTER, England — Two new randomized controlled trials (RCTs) assessing the role of rituximab in the treatment of various stages of systemic lupus erythematosus (SLE) have the green light to ...

The syndrome, termed ... Women with the autoimmune diseases rheumatoid arthritis, lupus or systemic sclerosis may have a higher rate of death related to cardiovascular disease than men with the ...

Medscape Medical News, May 28, 2025 Novel Autoantibodies Linked to Thrombosis Risk in Lupus Anti-TFAM antibodies are detected in about one third of patients with systemic lupus erythematosus and ...

In contrast to relapsing‐remitting patterns, persistently active disease (PAD) is a disease activity pattern in patients with systemic lupus erythematosus (SLE) that is inadequately studied.

Systemic Lupus Erythematosus (SLE), more commonly known as lupus, is a chronic autoimmune condition. Its symptoms are mostly similar to that of other diseases, making it notoriously difficult to ...

The study, published in ACR Open Rheumatology, explored data on factors motivating participation, or lack thereof, in clinical trials for patients with systemic lupus erythematosus (SLE ...